Hims & Hers Pulls Back GLP-1 Weight-Loss Pill Shortly afterward, Hims & Hers Health abruptly abandoned its plan to launch a compounded version oral weight-loss pill priced as low as $49/month, backing off within days amid regulatory pressure and industry backlash
Our Score: 4/5 What Is Ro
Marston, Eastern District of Pennsylvania Number of Cases: Approximately 2,947 pending cases (and growing rapidly) Defendants: Novo Nordisk and Eli Lilly Covered Drugs: Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Victoza, Saxenda, Trulicity Key Developments: August 15, 2025 - Landmark Ruling: Judge Marston ruled that gastroparesis claims require objective diagnostic testing (gastric emptying scan)
Drug-drug interactions that lower drug exposure might result in treatment failure